| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.35▲ | 2.33▲ | 2.32▲ | 2.28▲ | 2.23▲ |
| MA10 | 2.34▲ | 2.31▲ | 2.29▲ | 2.25▲ | 2.16▲ |
| MA20 | 2.33▲ | 2.29▲ | 2.27▲ | 2.27▲ | 2.68▼ |
| MA50 | 2.30▲ | 2.29▲ | 2.26▲ | 2.16▲ | 3.17▼ |
| MA100 | 2.28▲ | 2.25▲ | 2.26▲ | 2.73▼ | 2.99▼ |
| MA200 | 2.27▲ | 2.26▲ | 2.21▲ | 3.10▼ | 2.45▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | 0.009▲ | 0.010▲ | 0.007▲ | -0.010▼ |
| RSI | 64.058▲ | 66.837▲ | 64.197▲ | 56.896▲ | 43.765▼ |
| STOCH | 77.500 | 94.062▲ | 92.536▲ | 55.854 | 45.287 |
| WILL %R | -28.571 | -6.452▲ | -6.452▲ | -30.564 | -79.573▼ |
| CCI | 110.814▲ | 122.940▲ | 156.380▲ | 64.727 | 10.770 |
|
Wednesday, October 29, 2025 10:14 PM
Despite a recent pullback to $2.30, Cardiff Oncology's stock is exhibiting notable strength. Market experts remain optimistic, with six analysts maintaining a "Moderate Buy" recommendation and ...
|
|
Saturday, October 25, 2025 04:49 AM
Cardiff Oncology (CRDF) is a speculative buy with potential blockbuster gains ahead of its 2026 data readout. Read here for more analysis.
|
|
Wednesday, October 22, 2025 04:44 AM
Cardiff Oncology's onvansertib's unique PLK1 inhibition mechanism offers breakthrough potential in multi-billion-dollar cancer markets. See why CRDF stock is a Buy.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 31/10/25 | 2.21 | 2.36 | 2.20 | 2.35 | 629,000 |
| 30/10/25 | 2.21 | 2.28 | 2.21 | 2.23 | 647,500 |
| 29/10/25 | 2.31 | 2.31 | 2.21 | 2.24 | 627,600 |
| 28/10/25 | 2.34 | 2.38 | 2.28 | 2.30 | 1,050,183 |
| 27/10/25 | 2.26 | 2.3265 | 2.24 | 2.29 | 859,000 |
| 24/10/25 | 2.22 | 2.25 | 2.1845 | 2.23 | 731,945 |
| 23/10/25 | 2.15 | 2.24 | 2.15 | 2.21 | 466,817 |
| 22/10/25 | 2.21 | 2.22 | 2.1001 | 2.16 | 685,459 |
| 21/10/25 | 2.25 | 2.27 | 2.16 | 2.23 | 757,409 |
| 20/10/25 | 2.24 | 2.33 | 2.22 | 2.28 | 884,628 |
|
|
||||
|
|
||||
|
|